{
    "organizations": [],
    "uuid": "87dbda412529b15c5851498115cc01f15c4cdace",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bristol-myers-squibbs-opdivo-now-t/brief-bristol-myers-squibbs-opdivo-now-the-first-and-only-fda-approved-pd-1-inhibitor-to-offer-every-four-week-dosing-idUSFWN1QO0EA",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Squibb's Opdivo Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Bristol-Myers Squibb Co:\n* BRISTOL-MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) NOW THE FIRST AND ONLY FDA-APPROVED PD-1 INHIBITOR TO OFFER EVERY FOUR-WEEK DOSING\n* BRISTOL-MYERS SQUIBB - ‍ OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS​\n* BRISTOL-MYERS SQUIBB - FDA APPROVES OPDIVO LABEL UPDATE OFFERING FLEXIBLE FLAT-DOSING OPTIONS EVERY TWO WEEKS (240 MG) OR EVERY FOUR WEEKS (480 MG)​\n* BRISTOL-MYERS SQUIBB CO - ‍DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T20:09:00.000+02:00",
    "crawled": "2018-03-07T19:54:14.038+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "squibb",
        "co",
        "squibb",
        "nivolumab",
        "first",
        "inhibitor",
        "offer",
        "every",
        "dosing",
        "squibb",
        "opdivo",
        "also",
        "approved",
        "shorter",
        "infusion",
        "across",
        "approved",
        "squibb",
        "fda",
        "approves",
        "opdivo",
        "label",
        "update",
        "offering",
        "flexible",
        "option",
        "every",
        "two",
        "week",
        "mg",
        "every",
        "four",
        "week",
        "mg",
        "squibb",
        "co",
        "schedule",
        "update",
        "additional",
        "approved",
        "indication",
        "opdivo",
        "may",
        "submitted",
        "fda",
        "future",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}